These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 28011961)
21. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400 [TBL] [Abstract][Full Text] [Related]
22. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. Chui CK; Dong WW; Joy JB; Poon AF; Dong WY; Mo T; Woods CK; Beatty C; Hew H; Harrigan PR; Brumme CJ J Clin Microbiol; 2015 Sep; 53(9):2942-50. PubMed ID: 26135875 [TBL] [Abstract][Full Text] [Related]
23. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Di Maio VC; Cento V; Di Paolo D; Aragri M; De Leonardis F; Tontodonati M; Micheli V; Bellocchi MC; Antonucci FP; Bertoli A; Lenci I; Milana M; Gianserra L; Melis M; Di Biagio A; Sarrecchia C; Sarmati L; Landonio S; Francioso S; Lambiase L; Nicolini LA; Marenco S; Nosotti L; Giannelli V; Siciliano M; Romagnoli D; Pellicelli A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Taliani G; Mastroianni C; Vespasiani-Gentilucci U; Romano M; Morisco F; Gasbarrini A; Vullo V; Bruno S; Baiguera C; Pasquazzi C; Tisone G; Picciotto A; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F; J Antimicrob Chemother; 2016 Mar; 71(3):739-50. PubMed ID: 26679249 [TBL] [Abstract][Full Text] [Related]
24. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches. de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789 [TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586 [TBL] [Abstract][Full Text] [Related]
26. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555 [TBL] [Abstract][Full Text] [Related]
27. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
28. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Beloukas A; King S; Childs K; Papadimitropoulos A; Hopkins M; Atkins M; Agarwal K; Nelson M; Geretti AM Clin Microbiol Infect; 2015 Nov; 21(11):1033-9. PubMed ID: 26232533 [TBL] [Abstract][Full Text] [Related]
29. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Cento V; Landonio S; De Luca F; Di Maio VC; Micheli V; Mirabelli C; Niero F; Magni C; Rizzardini G; Perno CF; Ceccherini-Silberstein F Antivir Ther; 2013; 18(4):645-8. PubMed ID: 23411358 [TBL] [Abstract][Full Text] [Related]
30. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Andonov A; Kadkhoda K; Osiowy C; Kaita K Can J Gastroenterol; 2013 Jul; 27(7):414-6. PubMed ID: 23862174 [TBL] [Abstract][Full Text] [Related]
31. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients. Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893 [TBL] [Abstract][Full Text] [Related]
32. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K. Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817 [TBL] [Abstract][Full Text] [Related]
33. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study. Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073 [TBL] [Abstract][Full Text] [Related]
34. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809 [TBL] [Abstract][Full Text] [Related]
35. Significance of mutations in the region coding for NS3/4 protease in patients infected with HCV genotype 1b. Łapiński TW; Rogalska-Płońska M; Kowalczuk O; Kiśluk J; Zurnowska J; Nikliński J; Flisiak R Adv Clin Exp Med; 2018 Nov; 27(11):1593-1600. PubMed ID: 30048050 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. Vicenti I; Falasca F; Sticchi L; Bruzzone B; Turriziani O; Zazzi M J Clin Virol; 2016 Mar; 76():20-3. PubMed ID: 26802683 [TBL] [Abstract][Full Text] [Related]
37. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. McCloskey RM; Liang RH; Joy JB; Krajden M; Montaner JS; Harrigan PR; Poon AF J Infect Dis; 2015 Apr; 211(8):1288-95. PubMed ID: 25389307 [TBL] [Abstract][Full Text] [Related]
38. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France. Hajji H; Aherfi S; Motte A; Ravaux I; Mokhtari S; Ruiz JM; Poizot-Martin I; Tourres C; Tivoli N; Gérolami R; Tamalet C; Colson P J Med Virol; 2015 Nov; 87(11):1921-33. PubMed ID: 25959702 [TBL] [Abstract][Full Text] [Related]